Active	Status	Sponsor type	Region	Phase	Filter
22 Active 0 Inactive 22 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

22 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Tanaka, Shigeya
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Kitamura, Shigekazu
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Yamaguchi, Michio
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Carotenuto, Marco
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Yamanaka, Gaku
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26
PIONEER-PEDS1, NCT04396236 / 2019-004378-24: A Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1633	Europe, Japan, US, RoW	Lasmiditan, LY573144, Placebo	Eli Lilly and Company	Migraine	01/25	01/25
PIONEER-PEDS2, NCT04396574 / 2019-004379-38: A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine	Recruiting	3	1000	Europe, Japan, US, RoW	Lasmiditan, LY573144	Eli Lilly and Company	Migraine	03/26	03/26
Bajpai, Vinay
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
Jog, Pramod
REBUILD-2, NCT04616326 / 2018-004622-28: A Study of Galcanezumab (LY2951742) in Participants 12 to 17 Years of Age With Chronic Migraine	Recruiting	3	300	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Chronic Migraine	07/25	03/26
REBUILD, NCT03432286 / 2017-004351-23: A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine	Recruiting	3	325	Europe, Japan, US, RoW	Galcanezumab, LY2951742, Placebo	Eli Lilly and Company	Episodic Migraine	11/25	11/26